Cellipont Bioservices Advances Six Cell Therapy Programs to 2026 IND Submissions
- Cellipont's Texas facility is supporting six client cell therapy projects targeting IND submissions in 2026.
- The CDMO provides integrated process development, GMP manufacturing, analytical testing, and regulatory preparation for autologous and allogeneic programs.
Operational Impact
Cellipont's six concurrent IND-stage programs signal expanded cell therapy manufacturing capacity and regulatory readiness at its Texas facility, relevant for sponsors evaluating CDMO partners for near-term clinical advancement.
Source: PharmaSource RSS
Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines
- Northway Biotech inaugurated a 3,500-square-meter cGMP facility in Vilnius, Lithuania, backed by €61 million investment from Northway Group.
- The center operates up to 20 independent cGMP manufacturing lines for autologous and allogeneic cell therapies, personalized vaccines, and regenerative medicine.
- Facility begins operations with first customers and contracts already secured; supports biotech, pharma, university hospitals, and research institutions.
Operational Impact
Northway's Vilnius facility adds dedicated cell-therapy and regenerative-medicine cGMP capacity in Eastern Europe, offering CDMO directors a new regional option for autologous/allogeneic cell manufacturing and personalized vaccine development with segregated multi-product infrastructure.
Source: PharmaSource RSS
References
- PharmaSource RSS — [Cellipont Bioservices Advances Six Cell Therapy Programs to 2026 IND Submissions](https://pharmasource.global/content/news/cdmo-news/cellipont-bioservices-supports-six-cell-therapy-projects-targeting-2026-ind-submissions)
- PharmaSource RSS — Northway Biotech Opens €61M Cell Therapy CDMO in Vilnius with 20 cGMP Lines